Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178173 · ClinicalTrials.gov registry record · NA
Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 230
- Enrollment target
NCT05178173: Completed NA study, sponsored by University of North Carolina, Chapel Hill.
NCT05178173 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05178173, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
Study Summary
Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used according to on-label instructions. Patients will be randomized to a mouthrinse and will be asked to give a saliva sample immediately before and after a one minute mouthwash. Saliva samples will be collected from patients at 15 minute intervals thereafter up to an hour (15, 30, 45 and 60 minutes). The samples will be stored and used for real-time reverse transcription polymerase chain reaction (RT-PCR) detection of viral SARS-CoV-2 RNA and viral infectivity assays. Patients will also complete a short-survey on the taste and experience of using the mouthwash. This study involves 150 subject participants and one, 75-90 minute visit.
Primary Outcome
Determination of qPCR of inactivity of SARS-CoV-2 cellular infectivity in COVID-19 positive patient saliva
Interventions
- OTHER Placebo Comparator: Sterile Water
- OTHER 27% Ethanol plus essential oils
- OTHER 0.075% Cetylpyridinium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2023-07-12 |
| Phase | NA |
What the finished NCT05178173 record still lists
NCT05178173 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator: Sterile Water is the first listed.
NCT05178173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05178173 about?
NCT05178173 is a clinical study titled "Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)". Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65 years old. All mouthrinses are commercially available and will be used a...
What is the current status of trial NCT05178173?
This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2022-01-20. Estimated completion is 2023-07-12.
What interventions are being tested in trial NCT05178173?
The interventions under investigation include: Placebo Comparator: Sterile Water (OTHER), 27% Ethanol plus essential oils (OTHER), 0.075% Cetylpyridinium Chloride (OTHER).
Who is sponsoring clinical trial NCT05178173?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05178173's enrollment target sits among peer trials
230 465th of 2000 higher than 1,533 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI